Artwork

Anuj Desai에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 Anuj Desai 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.
Player FM -팟 캐스트 앱
Player FM 앱으로 오프라인으로 전환하세요!

EPISODE #161 Cannabis Vs. Opioids with Valentino Parravicini, Chief Scientific Officer at Oxford Cannabinoid Technologies

43:00
 
공유
 

Manage episode 328711290 series 2522512
Anuj Desai에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 Anuj Desai 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.

This week, we’re joined by Valentino Parravicini, Chief Scientific Officer at Oxford Cannabinoid Technologies - British pharmaceutical company developing a portfolio of next-generation prescription cannabinoid medicines.

In this episode, we explore the potential use of cannabis-based medicines as a replacement for prescription opioids, their safety profile, and their use cases as analgesics.

📚 VIEW SHOW NOTES AND EXTRAS:

https://www.canverse.global/shownotes/e161

About Valentino Parravicini

Valentino has spent his academic career at the NIH (NIAMS-USA) working in allergy and inflammation and discovering a new signalling pathway in mast cells. After moving to the National Institute for Medical Research, Mill Hill (NIMR, now part of the Francis Crick), he focussed on animal models of inflammation and autoimmunity. He has been Visiting Scientist at Imperial College London and King’s College London.

Valentino has over 12 years of experience in drug discovery and development accrued working in Big Pharma and SMEs. He worked at Roche (Italy), and at the Epigenetic Drug Performance Unit of the Immune-Inflammation Therapeutic Area of GlaxoSmithKline (GSK, UK).

He was also involved in the set-up of two start-up biotechnology companies, first at Kesios Therapeutics (oncology), and the at GammaDelta Therapeutics (cell and gene therapy in oncology), which was recently acquired by Takeda. He has lead research teams and programmes in the fields of immune-inflammation, oncology, and virology, both in small molecules and cell therapy, applied to early research and drug discovery and development.

He most recently joined Oxford Cannabinoid Technologies as Chief Scientific Officer where he contributed to shaping the cannabinoid-based R&D pipeline and overall scientific strategy leading to the Company’s IPO in May 2021.

Resources

Join Valentino on Linkedin: https://www.linkedin.com/in/valentino-parravicini/?originalSubdomain=uk

Follow Oxford Cannabinoid Technologies on Linkedin: https://www.linkedin.com/company/oxford-cannabinoid-technologies/

Oxford Cannabinoid Technologies Website: https://www.oxcantech.com/

  continue reading

194 에피소드

Artwork
icon공유
 
Manage episode 328711290 series 2522512
Anuj Desai에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 Anuj Desai 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.

This week, we’re joined by Valentino Parravicini, Chief Scientific Officer at Oxford Cannabinoid Technologies - British pharmaceutical company developing a portfolio of next-generation prescription cannabinoid medicines.

In this episode, we explore the potential use of cannabis-based medicines as a replacement for prescription opioids, their safety profile, and their use cases as analgesics.

📚 VIEW SHOW NOTES AND EXTRAS:

https://www.canverse.global/shownotes/e161

About Valentino Parravicini

Valentino has spent his academic career at the NIH (NIAMS-USA) working in allergy and inflammation and discovering a new signalling pathway in mast cells. After moving to the National Institute for Medical Research, Mill Hill (NIMR, now part of the Francis Crick), he focussed on animal models of inflammation and autoimmunity. He has been Visiting Scientist at Imperial College London and King’s College London.

Valentino has over 12 years of experience in drug discovery and development accrued working in Big Pharma and SMEs. He worked at Roche (Italy), and at the Epigenetic Drug Performance Unit of the Immune-Inflammation Therapeutic Area of GlaxoSmithKline (GSK, UK).

He was also involved in the set-up of two start-up biotechnology companies, first at Kesios Therapeutics (oncology), and the at GammaDelta Therapeutics (cell and gene therapy in oncology), which was recently acquired by Takeda. He has lead research teams and programmes in the fields of immune-inflammation, oncology, and virology, both in small molecules and cell therapy, applied to early research and drug discovery and development.

He most recently joined Oxford Cannabinoid Technologies as Chief Scientific Officer where he contributed to shaping the cannabinoid-based R&D pipeline and overall scientific strategy leading to the Company’s IPO in May 2021.

Resources

Join Valentino on Linkedin: https://www.linkedin.com/in/valentino-parravicini/?originalSubdomain=uk

Follow Oxford Cannabinoid Technologies on Linkedin: https://www.linkedin.com/company/oxford-cannabinoid-technologies/

Oxford Cannabinoid Technologies Website: https://www.oxcantech.com/

  continue reading

194 에피소드

모든 에피소드

×
 
Loading …

플레이어 FM에 오신것을 환영합니다!

플레이어 FM은 웹에서 고품질 팟캐스트를 검색하여 지금 바로 즐길 수 있도록 합니다. 최고의 팟캐스트 앱이며 Android, iPhone 및 웹에서도 작동합니다. 장치 간 구독 동기화를 위해 가입하세요.

 

빠른 참조 가이드